That the Parliament welcomes a ground-breaking new imaging approach that enables earlier, more accurate and reliable diagnoses of prostate cancer; notes that it is being pioneered by researchers at Heriot-Watt University and Less Grey Imaging, a spinout company from the University; understands that the approach complements existing clinical ultrasound equipment by providing increased clarity and precision of prostate biopsies and access to faster tests; believes that earlier diagnoses also benefit the treatment of prostate cancer by giving patients with access to a greater range of options; recognises with deep concern that prostate cancer is the most common cancer in men in Scotland, which makes it a critical healthcare challenge; understands that up to 28% of prostate tumours are currently being missed, which reduces the likelihood of good cancer outcomes; further understands that this technology has an initial 94% sensitivity rate in tumour detection in an ongoing clinical trial funded by the Chief Scientist Office Scotland; believes that this innovative research has the potential to help the NHS in providing equal access to early opportunities for early diagnosis and treatment across Scotland and also to position Scotland as a leader in medical innovation, and hopes for future success in further clinical trials and eventual fast integration into diagnostic pathways to realise tangible benefits to patients and the NHS.